form8-k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
     
Date of Report (Date of Earliest Event Reported):
  
March 5, 2008 (March 5, 2008)

 
Endo Pharmaceuticals Holdings Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
001-15989
  
13-4022871
_____________________
(State or other jurisdiction
  
_____________
(Commission
  
______________
(I.R.S. Employer
of incorporation)
  
File Number)
  
Identification No.)
  
        
100 Endo Boulevard, Chadds Ford, PA
      
19317
_________________________________
(Address of principal executive offices)
      
___________
(Zip Code)

     
Registrant’s telephone number, including area code
  
(610) 558-9800
 
Not Applicable
______________________________________________
Former name or former address, if changed since last report
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 7.01 Regulation FD Disclosure
 
On March 5, 2008, the Chairman of the Board of Directors of the Registrant sent a letter to D. E. Shaw Valence Portfolios, L.L.C., a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
 
 
Item 9.01. Financial Statements and Exhibits.
 
 (d)
 
Exhibits
 
    
 
Exhibit No.
  
Description
 
99.1
 
  
Letter dated March 5, 2008
 
 

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


 
ENDO PHARMACEUTICALS HOLDINGS INC.
 
(Registrant)
  
         
         
 
By:
/s/ Caroline B. Manogue
  
   
Name:
Caroline B. Manogue
  
   
Title:
Executive Vice President, Chief Legal Officer & Secretary




Dated:  March 5, 2008
 
 
 
 
 
 
INDEX TO EXHIBITS

Exhibit No.
Description
   
99.1
Letter dated March 5, 2008